[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368364-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368364-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","molecular-tumour-board-in-gastrointestinal-cancers","Molecular tumour board in gastrointestinal cancers","","Molecularly guided treatment relies on comprehensive genomic profiling (CGP) to select options for individual patients, but real-world evidence for molecular tumour boards (MTBs) in gastrointestinal cancers remains limited. This retrospective study analyzed advanced GI cancer cases discussed in an MTB between Aug 2019 and Dec 2024, assessing outcomes after MTB-recommended MGTOs versus standard care, including real-world progression-free survival and an MTB effectiveness metric using the growth modulation index.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/molecular-tumour-board-in-gastrointestinal-cancers/368364/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/molecular-tumour-board-in-gastrointestinal-cancers/368364.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about molecular tumour boards in gastrointestinal cancers?","Question",{"text":63,"@type":64},"The study evaluates the clinical value of implementing MTBs to guide treatment decision making using molecularly guided treatment options for patients with gastrointestinal cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were outcomes measured after applying MTB recommendations?",{"text":68,"@type":64},"The study used real-world progression-free survival and overall survival, and quantified MTB effectiveness with the growth modulation index (ratio of PFSMTB to PFSprior).",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings regarding progression-free survival and overall survival?",{"text":72,"@type":64},"Patients receiving MGTOs showed longer real-world progression-free survival than standard therapies, while no overall survival difference was observed between MGTOs and standard treatments.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368364,1790398185,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","ORIGINAL ARTICLE  \nMolecular tumour board in gastrointestinal cancers  \nL. Boscolo Bielo1, 2, E. Crimini1, 2, M. Repetto3, M. Barberis4, E. Battaiotto1 , 2, J. Katrini1, 2, E. Martino1, G. Gaudio1,  \nM. Lombardi4, C. Zanzottera5, G. Aurilio5, C. Belli1, Y. Zhan4, V. Fuorivia1, 2, R. M. Marsicano1, 2, J. D. Etessami1, 2, P. Zagami1, A. Marra1, D. Trapani1, 2, B. Taurelli Salimbeni1, C. Criscitiello1, 2, D. Ciardiello6, B. Lavinia6, L. Gervaso6, C. A. Cella6,  \nF. Spada6, M. G. Zampino6, N. Fusco2, 7, N. Fazio6, E. Guerini Rocco2, 7 & G. Curigliano1, 2 􀀁  \n1Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan; 2Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy; 3Early Drug Development Service, Memorial Sloan-Kettering Cancer Center, New York, USA; 4Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan; 5Division of Cancer Prevention and Genetics, European Institute of Oncology (IEO) IRCCS, Milan; 6Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Milan; 7Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy  \nAvailable online xxx  \nBackground: Comprehensive genomic proﬁling (CGP) is being increasingly adopted in clinical practice to guide the use of molecularly guided treatment options (MGTOs) . To optimize the integration of MGTOs in routine cancer care, molecular tumour boards (MTBs) have been established. Limited data are available to address the clinical value of implementing MTBs to inform treatment decision making in patients with gastrointestinal (GI) cancers.  \nMaterials and methods: We retrospectively retrieved medical records from patients with advanced GI cancers discussed at the European Institute of Oncology’s MTB between August 2019 and December 2024 . We evaluated clinical outcomes resulting from applying MGTOs in cancer care according to MTB recommendations, describing real-world progression-free (rwPFS) and overall survival (OS), and used the growth modulation index (GMI) (ratio of PFSMTB to PFSprior) to quantify the effectiveness of MTB’s recommended cancer treatment in extending PFS.  \nResults: Among 192 patients with GI cancers discussed at MTB, 139 (72 .3%) received an MTB treatment recommendation. For patients with available follow-up data (n ¼ 82), 31 patients (41 .4%, 17 .7% overall) received MGTOs, while 51 patients received standard treatments. Patients receiving MGTOs exhibited a longer rwPFS compared with cases receiving standard therapies [5.35 versus 3.55 months, hazard ratio (HR) 0.62, 95% conﬁdence interval (CI) 0 .36-1.08, P ¼ 0.08] and with unmatched cases showing actionable biomarkers but not treated with targeted agents (n ¼ 31) (rwPFS 5 .35 versus 2 .40 months, HR 0 .49, 95% CI 0 .27-0.90, P ¼ 0.02) . The use of MGTOs resulted in a GMI of 1 . 12 (interquartile range 0 .68-2.36) . The European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT) tier I-III treatments resulted in a restricted mean PFS gain of 4.87 months compared with standard therapies (95% CI 1 .02-8.72 months, P ¼ 0.01) . No OS difference was observed between patients receiving MGTOs and standard treatments (P ¼ 0.89) .  \nConclusions: Our results suggest that MTB-informed clinical decision making could provide valuable clinical beneﬁts and expanded therapeutic options in patients affected by advanced GI cancers.  \nKey words: gastrointestinal cancers, molecular tumour board, precision medicine, next-generation sequencing, target therapy, genomic proﬁling  \nINTRODUCTION  \nThe advent of precision oncology transformed the therapeutic landscape for cancer treatment, emphasizing a biomarker-driven approach to tailor systemic therapies to  \n*Correspondence to: Prof. Giuseppe Curigliano, Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, via G. Ripamonti 4","cbCaiqFoBmmYuFgJ","https://ap.wps.com/l/cbCaiqFoBmmYuFgJ","pdf",578119,"English","# Background\n# Materials and methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What question does the study address about molecular tumour boards in gastrointestinal cancers?\",\"answer\":\"The study evaluates the clinical value of implementing MTBs to guide treatment decision making using molecularly guided treatment options for patients with gastrointestinal cancers.\"},{\"question\":\"How were outcomes measured after applying MTB recommendations?\",\"answer\":\"The study used real-world progression-free survival and overall survival, and quantified MTB effectiveness with the growth modulation index (ratio of PFSMTB to PFSprior).\"},{\"question\":\"What were the main findings regarding progression-free survival and overall survival?\",\"answer\":\"Patients receiving MGTOs showed longer real-world progression-free survival than standard therapies, while no overall survival difference was observed between MGTOs and standard treatments.\"}]","Molecular tumour board in gastrointestinal cancers | PDF",1790176536,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3355cdc18b15b8a1ec891fb944fd7d3.webp",983,1269,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcbe6a3ead52fb5095484a92c1b3ddca.webp",982,1268,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f32c0873caf1d519e9c6a1246bd1dc6.webp",981,1266,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c942bf35cc5f37455bd0615cc00a3826.webp",980,1265]